The FDA approved pembrolizumab monotherapy for patients with metastatic small cell lung cancer that progressed on or after platinum-based chemotherapy and at least one other prior line of therapy.

This marks the first approval of pembrolizumab (Keytruda, Merck), an anti-PD-1 therapy, for small cell lung cancer.